The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
about
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateProresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis.Combination therapy with biologic agents in rheumatic diseases: current and future prospectsThe supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritisCardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature.Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritisEfficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.DAS steered therapy in clinical practice; cross-sectional results from the METEOR databaseCost per responder of TNF-α therapies in Germany.Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)Effective treatment of rat adjuvant-induced arthritis by celastrol.Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial.Mechanistic biomarkers for clinical decision making in rheumatic diseases.Rheumatoid arthritis--early diagnosis and disease managementCombination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo.Age affects joint space narrowing in patients with early active rheumatoid arthritis.Rheumatologists' adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission.Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.Disease control with glucocorticoid therapy in rheumatoid arthritis.Drug therapy in undifferentiated arthritis: a systematic literature review.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper.Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Treat to Target in Axial Spondyloarthritis: What Are the Issues?Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsSpectacular improvement in vitamin D status in elderly osteoporotic women: 8-year analysis of an osteoporotic population treated in a dedicated fracture liaison service.A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.Rheumatoid arthritis in the Kingdom of Saudi Arabia.Guidelines for the drug treatment of rheumatoid arthritis.
P2860
Q26800154-2235EA7C-0F57-4353-BA0C-6719B2BEB7E7Q26859134-600E52D7-988C-4F35-AA99-BB9DF01633B8Q27334082-18E20D1A-1B56-451B-8F12-9DF85A6D407DQ28066250-E03F5059-D4AD-4CA8-B3B4-900581095F99Q28084878-4DA69D4F-70F5-4388-B055-6EA34341C30AQ33713206-4F1B33F8-1D00-4397-BE01-2CE53074CF4DQ34374946-26152575-3788-4C18-B918-524CD41BFE15Q35041283-73104510-AF92-4CF3-8B16-5A039159BD9CQ35084199-C2DAEFA5-1655-4324-908E-289D4868907FQ35895890-D694778D-30F4-4173-A762-5611589B4B9CQ35981155-57A0BE5C-6EDE-43C0-8CBF-1B21B6FC3EEBQ36485495-B6F63E6D-5843-4FBF-A0F6-5736F72A3CEFQ36638712-06C78FA5-A7A3-4883-A720-96498F630DA3Q36773674-E9E3D315-93A4-4352-BCE8-67204F0DA40DQ36905584-8CA904DB-5D9D-4EDC-BDA3-AC3FF43C1A33Q37043713-ADC4CE36-0978-40C0-A115-D03B1FB09A50Q37249844-EE9CFD5A-8AE2-4F65-A10A-2209842999C5Q37356083-BD69952E-03C8-4DB3-BFF2-51619E7233C5Q37622216-FBA951AF-DAFD-410D-B001-B047433E0469Q37728501-9CF274EA-6124-4E81-9234-74A18260E855Q38017653-67F01C85-833A-43C5-8C55-2EA286708D8DQ38112676-31708766-4CCA-4F62-920C-1736211A7225Q38128726-11220195-22BF-4384-A69D-0591A9E6B096Q38176549-38AB104F-4EDD-4F92-8EFF-DFDDA07BAD7CQ38189108-A7FA3846-7AE3-4FCD-A5EC-355D7D2FDD41Q38195248-3896F319-CBC1-4F92-864D-7703F98C5B9CQ38204350-4E4AF6FF-4A42-4E44-9FB9-A468926E5C0EQ38211695-0B470D6C-73C1-4C45-BAD1-DC2C9EB326E4Q38372369-21CA87D0-414F-4D2A-BBF3-CE763CE5DBC8Q39225782-61EF2A8F-35EE-458F-BD29-3F7F5DC56D97Q39230189-11718EBC-9633-481B-A860-26B2C029471DQ40062771-48F841D6-C3B3-42FC-A7FB-6C15E76546BAQ40153893-60E15109-2861-4724-B2EB-9C37D38CA183Q40591907-7AD4FBC4-3888-49FE-8DB1-2A9D53190CBAQ40664154-B5A20D0C-DA02-4BC5-8BA0-A1752545CB58Q41450339-67A8911A-B0CF-4209-A72A-4295E72E2DF2Q41646567-15544ABC-A812-42CA-831D-186B4C757597Q41925567-2D959EDF-1611-4CB1-846A-3C8D4C996476Q42547058-E357B3EA-568A-49B5-862C-8F6BC035FE0EQ43675571-21E1C186-7804-4656-9AC0-08415A949D70
P2860
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The impact of four dynamic, go ...... is patients in the BeSt study.
@en
The impact of four dynamic, go ...... is patients in the BeSt study.
@nl
type
label
The impact of four dynamic, go ...... is patients in the BeSt study.
@en
The impact of four dynamic, go ...... is patients in the BeSt study.
@nl
prefLabel
The impact of four dynamic, go ...... is patients in the BeSt study.
@en
The impact of four dynamic, go ...... is patients in the BeSt study.
@nl
P2093
P356
P1476
The impact of four dynamic, go ...... is patients in the BeSt study.
@en
P2093
Ben A C Dijkmans
Cornelia F Allaart
H Karel Ronday
K Huub Han
Melek Güler-Yüksel
Naomi B Klarenbeek
Patrick E H Seys
Pit J S M Kerstens
Sjoerd M van der Kooij
Tom W J Huizinga
P304
P356
10.1136/ARD.2010.141234
P407
P577
2011-03-17T00:00:00Z